This policy brief provides a quantitative analysis of how the Inflation Reduction Act’s (IRA) policy to set prices for select small molecule drugs 9 years after FDA approval impacts innovation and patient health. Price setting under the IRA undermines existing...
This policy brief analyzes the impact of regulatory and legislative changes within the Inflation Reduction Act (IRA) on medical R&D and patient health with respect to small molecule drugs. Initial evidence potentially suggests that the cutbacks in R&D have...
The Biden administration has made reducing health disparities a major goal of its health care agenda. This paper provides analysis of whether and how biopharmaceutical innovation has historically reduced disparities in health outcomes and how reducing such innovation...
This paper provides the first quantitative economic models of pharmacy benefit management (PBM) regulation. Indeed, few economic models of the pharmaceutical industry even acknowledge that drug benefits are managed and that companies specialize in benefit management....
In February 2022, the Biden Administration aimed to reignite the Cancer Moonshot through its proposed federal budget and stated that one of its objectives is to reduce cancer mortality by 50% over the next 25 years. Currently, there is already a very large amount of...